Skip to main content
Download PDF

Effects of probiotic supplementation with weight reducing intervention on anthropometric measures, body composition, eating behavior, and related hormone levels in patients with food addiction and weight regain after bariatric surgery: a study protocol for a randomized clinical trial

BMC Nutrition volume 9, Article number: 63 (2023) Cite this article

Abstract

Background

One of the unfortunate events after bariatric surgery is the weight regain, which occurs in some patients. Food addiction is an eating disorder related to the brain-intestinal axis and can be effective in weight regain after bariatric surgery. In addition, the gut microbiome plays a vital role in eating behaviors, including food addiction. So, this study will aim to evaluate the effects of probiotic supplementation with a weight-reducing diet and cognitive behavioral therapy on anthropometric measures, body composition, eating behavior, and related hormone levels, leptin, oxytocin, and serotonin, in patients with food addiction and weight regain after bariatric surgery.

Methods

We will carry out a triple-blinded randomized clinical trial for 12 weeks to evaluate the effect of probiotic supplementation with a weight-reducing diet and cognitive behavioral therapy on anthropometric measures, body composition, eating behavior, and related hormone levels including leptin, oxytocin, and serotonin, in patients with food addiction and weight regain after bariatric surgery.

Discussion

Based on the available evidence, probiotic supplementation by modifying the intestinal microbiome can improve food addiction and subsequent weight loss.

Trial Registration

Iranian Registry of Clinical Trials IRCT20220406054437N1 Registered on 2022–06-01.

Background

The growing prevalence of obesity in the world has made it a worrying epidemic [1]. Diet therapy, behavioral therapy, drug medication, and surgery treat obesity [2]. Currently, the most important, effective, safe, and long lasting treatment for severe obesity is bariatric surgery [3, 4]. However, not all patients undergoing bariatric surgery can maintain their weight loss, and some experience weight regains [5]. The prevalence of weight regain after bariatric surgery varies depending on the type of surgery, the length of time after surgery, and the definition of weight regain [5, 6]. Different factors affect weight maintenance or weight regain after bariatric surgery, including the type of surgery, eating behavioral disorders, body mass index, eating habits, anatomical changes of the gastrointestinal tract, hormonal changes, gut microbiome changes, access to healthy food, having exercise, and the existence of support groups [7,8,9]. With weight regain, diseases associated with obesity also return. It is also psychologically unbearable for the patient because the patient feels that he has lost his last way of treatment [6]. Eating disorders are the important factors affecting weight consequences after bariatric surgery, which need to be given more attention [10, 11]. One eating disorder that has recently come to the attention of researchers is food addiction. Food addiction is persistent, uncontrolled overeating of high-calorie foods (high in fat and sugar) associated with activating the brain s dopaminergic system or brain reward system [12]. Food addiction is also associated with other eating disorders such as binge eating and other mental disorders such as depression and anxiety [13,14,15]. The intestinal microbiome is one of the known influential regions that play an important role in the etiology of many diseases, including obesity; brain-intestinal axis signaling plays an important role in controlling food intake and energy homeostasis, followed by obesity [16]. Normal eating behaviors are coordinated by intestinal balance and extraintestinal hedonic and hemostatic mechanisms [17]. Growing studies on the role of intestinal microbiota in the etiology and progression of eating disorders have been done [18]. Intestinal bacteria can affect appetite control systems by producing metabolites such as lipopolysaccharide and flagellin in several ways: a) Effect on the secretion of digestive hormones such as cholecystokinin b) Effect on the central nervous system c) Increasing the permeability of the blood–brain barrier and increasing the effect of circulating cytokines on the appetite regulation center; Furthermore, intestinal bacteria affect the melanocortin system by producing peptides that mimic the function of neuropeptides such as α-MSH (α-melanocyte-stimulating hormone); bacteria also affect the appetite regulation system by producing neurotransmitters such as serotonin [18, 19]. There is also a correlation between mood, eating behavior, and intestinal microbiota, in that stress and depression increase the consumption of delicious foods; subsequently, it affects the growth of intestinal microbiota [20]. Also, autonomic changes, hormonal changes, and inflammation from stress and depression alter the gut microbiota [20]. Changes in the Brain-Gut-Microbiome system in food addiction shift the balance of the hedonic-homeostatic system toward a hedonic mechanism [17]. Hormones such as leptin, serotonin, and oxytocin, have an important role in the hedonic and homeostatic system and result from eating behaviors and food addiction [21,22,23,24,25]. Increased leptin concentrations are associated with addictive behaviors [26]. Also, intestinal microbiota, influenced by food intake, are effective in leptin expression and resistance [27,28,29,30]. Oxytocin is another hormone involved in food intake and eating behaviors [31]. Food intake activates oxytocin neurons in the hypothalamus, and fasting reduces oxytocin levels [32]. Oxytocin receptors are also present in many brain areas, including ventral tegmental and accumbens nuclei. They are involved in the brain reward system and hedonic pathway controlling appetite and food intake [32]. Oxytocin levels are closely related to intestinal microbiota (depletion of intestinal microorganisms leads to a significant reduction in oxytocin levels; also, Lactobacillus reuteri is involved in modulating oxytocin) [33,34,35]. Serotonin is another hormone that is effective in both the homeostatic and hedonic systems of food control [36]. Serotonin receptors are expressed in the dorsal striatum, an important area in eating behavior [36]. Activating the serotonin receptor reduces dopaminergic signaling and the desire for food intake [36]. The gastrointestinal tract contains a significant portion of serotonin, and the gut microbiota plays an important role in regulating serotonin; spore-forming bacteria lead to the synthesis of serotonin in enterochromaffin cells [37]. Serotonin is also involved in the development of food addiction; Low levels of serotonin in the brain lead to overeating delicious and sugar-rich foods, and increased blood glucose levels lead to increased absorption of the amino acid tryptophan and ultimately increase serotonin levels [38]. Bariatric surgery leads to anatomical, neurological, and physiological changes affecting the signaling of the homeostatic and hedonic systems, as well as changes in gastrointestinal hormones and intestinal microbiome, which profoundly affect eating behavior and subsequent weighting consequences [39]. Few interventions have been performed to deal with weight regain, mainly in medication, reoperation, and behavioral therapy. Researchers are also looking for ways to deal with regaining weight after bariatric surgery. Various studies have been performed on the effectiveness of probiotics on anthropometric indices, hormone levels, and eating behavior In obese people without surgery [40,41,42,43]. To date, no study has been performed on the effect of probiotics on people with food addiction and weight regain after bariatric surgery. The prevalence of food addiction in people who have undergone bariatric surgery is reported to be between 14–58% [44, 45]. Due to the significant prevalence of food addiction in patients undergoing bariatric surgery and its effect on the weight consequences of these patients, as well as changes in the intestinal microbiome and the role of the intestinal microbiome in hormonal changes and its relationship with food addiction, and, there are several studies on the effectiveness of probiotics in intestinal microbiota balance and improving food addiction and weight management in obese patients without bariatric surgery, therefore In this clinical trial study, the effect of probiotic supplementation on the improvement of outcome measures of weight control and levels of leptin, oxytocin, serotonin, followed by the improvement of food addiction and weight management of patients with food addiction and weight regain after bariatric surgery has been surveyed.

Objectives and hypothesis

This study aims to investigate the effect of probiotic supplementation with a weight-reducing diet and psychotherapy intervention on anthropometric measures, body composition, eating behavior, and related hormone levels (leptin, serotonin, oxytocin) in patients with food addiction and weight regain after bariatric surgery.

Methods and design

Study design

We will conduct a 12-week triple-blind randomized clinical trial. The flow chart of the study is presented in Figs. 1 and 2. This intervention will be performed in the nutrition clinic of Shahid Beheshti University of Medical Sciences in Tehran, Iran, to evaluate the effect of probiotic supplementation with a weight-reducing diet and psychotherapy on anthropometric measures, body composition, eating behavior, and related hormone levels in patients with food addiction and weight regain after bariatric surgery. The protocol is written in line with the Standard Protocol Items Recommendations for Interventional Trials (SPIRIT) checklist (Additional file 1) [46].

Fig. 1
figure 1

Protocol flow diagram; we will carry out a 12-week randomized controlled trial to determine the effects of probiotic supplementation with weight reducing diet on anthropometric measures, body composition, eating behavior, and related hormone levels in patients with food addiction and weight regain after bariatric surgery

Full size image
Fig. 2
figure 2

Timeline of the study; we expect the duration of the trial will be 20 months

Full size image

Sample size

The number of samples required for this study was calculated based on weight as a main dependent variable. The results of a previous study were used to calculate the sample size [47]. Sample size was calculated with α = 0.05 and power of 80% (1-β = 0.8). the sample size in each group was determined to be 20 patients; assuming a drop of 20%, 25 patients will be admitted to each group.

$$\begin{array}{c}\mathrm S1=2.8\\\mathrm S2\;=2.9\\\mathrm{Sp}\;=\;8.125\\\mathrm\mu1-\mathrm\mu2=2.5\\\end{array}$$
$$\begin{array}{c}\mathrm n=\frac{2\mathrm{Sp}^2\left({\mathrm Z}_{1-{\displaystyle\frac{\mathrm a}2}}+{\mathrm Z}_{1-\mathrm\beta}\;\right)^2}{\left(\mathrm\mu1-\mathrm\mu2\right)^2}\end{array}$$

Study population

Patients with weight regain after bariatric surgery, and food addiction will be recruited from the Obesity Surgery Center of Sina Hospital and Rasoul Akram Hospital in Tehran.

Weight regain in this study was defined as: At least 18 months have passed since the surgery, and at least 10% of the lowest weight has returned. The diagnosis of food addiction will be based on the Food Addiction Questionnaire (Modified Yale Food Addiction Scale; mYFAS 2.0) [48]. Subjects who meet the inclusion criteria will be thoroughly informed about the protocol of the study. In addition, each participant will sign the informed consent form.

Inclusion and exclusion criteria

For this study, 50 patients with weight regain and food addiction and with the following inclusion criteria will be included in the study: aged 18–50 years; BMI ≥ 25 kg/m2; willingness to participate in the study; not having diseases such as cancer, thyroid, renal or liver (except fatty liver); non-pregnant or lactating or menopause or professional athlete; not use of any antibiotics in the last three weeks and any protein or probiotic supplement in the last month.

Patients will be excluded if: taking any antibiotics during the study; using probiotic products (probiotic supplements, yogurt, cheese, cakes, biscuits, and probiotic pasta) or protein supplements during the study; using weight-loss or appetite-suppressing medications; pregnancy; consuming less than 90% of the supplements prescribed during the study Also, we will exclude participants who refuse to continue the study.

Randomization

This study is a triple-blind randomized controlled clinical trial. A simple method has been used for randomization. The randomization unit is Individual. Excel software has been used for randomization. Using unique codes as ID numbers, using random numbers generated by the software, participants were randomly assigned to the same volume in the intervention and placebo groups. (Description of randomization by Excel software: In the first step, we generated 50 random numbers according to the sample size, in the next step, we obtained the rank of these numbers obtained in the first step, and in the third step, we divided these numbers by 25, in the fourth step, the numbers that fell between zero and one were in the intervention group and the rest in the placebo group) The primary service method was used for allocation concealment, and someone outside our study performed allocation concealment and labeling of supplements.

Implementation

Potential participants will be invited to the study by FGT and AZ. The sequencing will be generated by AS, who is not going to assign participants into the study.

Intervention

For all participants in this study, the standard hypocaloric diet (-300 to -500 kcal from total energy requirement) is calculated based on basal metabolism (use of indirect calorimeter) and level of physical activity. The diet in each group will consist of 45% carbohydrates, 25% protein, and 30% fat. For all participants in the study, ten one-hour online individual sessions, once a week, will be performed cognitive behavioral therapy (CBT) intervention by a psychologist. This study will randomly divide participants into groups receiving a probiotic supplement or placebo. All participants are asked to take 2 capsules daily (after breakfast and after lunch) for 12 weeks. Capsules are given to participants at the beginning of the study and in the sixth week of the study, and they are asked to return the unused capsules. To follow the participants and ensure their adherence to diet and receive supplements, participants will be contacted by telephone once a week. Also, the participants will be followed up and evaluated in person at the end of the sixth and twelfth weeks. Because multi-strain probiotics are more effective than single-strain probiotics [49, 50], multi-strain probiotics will be used in this study. Each probiotic capsule contains Lactobacillus acidophilus (1.8 × 109 CFU / capsule), Bifidobacterium bifidum (1.8 × 109 CFU / capsule), Bifidobacterium lactis (1.8 × 109 CFU / capsule), Bifidobacterium longul / C, 1.8 (1 × 109 CFU / capsule), Lactobacillus reuteri (1 × 109 CFU / capsule), magnesium stearate and maltodextrin. The placebo capsule contains 300 mg of starch. The capsules are similar in shape, size, and color and are provided by Takgen Zist Company in Iran.

Adherence

To follow the participants and ensure their adherence to diet and receive supplements, participants will be contacted by telephone once a week. At every phone call, we will make sure if the cases are still in the study and they do not have exclusion criteria. Also, a 24-h recall is taken from patients on each phone call to ensure adherence to the diet. At the end of the sixth and twelfth weeks, the participants are followed up and evaluated in person. Individuals are asked to return unused supplements; if less than 90% of supplements are taken, the person will be excluded from the study. Data from patients who are more than 90% consistent with the intervention will be analyzed.

Study outcomes

The primary outcomes of this clinical trial are the changes in anthropometric indices (including weight, hip circumference, waist-to-hip ratio, fat mass, muscle mass) and food addiction score. Secondary outcomes are changes in eating behavior and serum levels of leptin, serotonin, and oxytocin.

If the patient has inclusion criteria, a consent form and personal information sheet will be completed for them.

Food addiction will be diagnosed using a Modified Yale Food Addiction Scale Version 2.0 questionnaire. In this questionnaire, 12 criteria are examined. Both the symptom count score and the clinical significance criterion are used. For the "diagnosis" scoring option, a participant can meet for mild, moderate, or severe food addiction. At the beginning of the study, in the middle of the study (sixth week), and at the end of the study (twelfth week), anthropometric measurements, body composition, and calculation of body mass index will be done for each person. A digital scale will measure weight with an accuracy of 0.1 kg, with minimal clothing and no shoes. Height, waist, and hip circumference will be measured with an inelastic meter with an accuracy of 0.5 cm. Waist circumference will be measured at a distance between the lowest rib and iliac bone and hip circumference at the highest hip protrusion. Body mass index and waist-to-hip ratio are obtained by calculation. Body fat mass and muscle mass will be measured by bioelectrical impedance analysis (BIA). The participants' physical activity level is assessed using the standard questionnaire of activities (metabolic equivalents task) (MET) at the start, the sixth week, and the end of the study. Eating behavior is assessed using the Three-Factor Eating Questionnaire (TFEQ-R18) at the beginning, sixth week, and end of the study. Three 24-h food recall (2 regular days of the week and one day off) will be taken from participants at the beginning, the sixth week, and end of the study, also, a 24-h recall once a week, with telephone calls with patients. To measure blood biochemical parameters, at the beginning and end of the study, after 12–14 h of night fasting, five cc of venous blood samples will be taken from the participants. Blood samples taken in tubes containing sodium citrate anticoagulants will be collected and centrifuged in the laboratory of the Shahid Beheshti Nutrition Faculty. Serums will be stored at -80 °C until the tests are performed. Serum levels of leptin, serotonin (LDN ELISA Kit, Germany), and oxytocin (Crystal Day ELISA Kit, Shanghai) will be measured by the ELISA method with the human kit with the intra-assay and inter-assay CV of < 10.8% (serotonin), < 12% (leptin), and < 6.8% (oxytocin) kits in the laboratory of the Nutrition Institute of Shahid Beheshti University of Medical Sciences.

Statistical analysis

In this study, data analysis will be performed by using SPSS version 21.0 (SPSS Inc, Chicago, Illinois) software. A paired t-test will be used to compare the mean of quantitative variables with normal distribution in each group between the beginning and the end of the study. The t-test will be used to compare the mean between the two groups at the beginning and end of the study. In the case of quantitative variables with non-normal distribution, Wilcoxon and Mann–Whitney tests are used, respectively. A repeated ANOVA test will be used for the variables measured three times during the study. Covariance analysis will be used to eliminate the effect of quantitative confounding factors. Quantitative confounding factors are physical activity and baseline values of the biochemical markers. A Chi-square test will be used to compare the qualitative variables between the two groups, and regression analysis will be used to eliminate the effect of qualitative confounding.

Ethical considerations

Patients with weight regain after bariatric surgery, and food addiction who meet the inclusion criteria will be thoroughly informed about the study's protocol. The protocol of this study was approved by the ethics committee of Shahid Beheshti University of Medical Sciences and conformed with the declaration of Helsinki (approved number IR.SBMU.NNFTRI.REC.1400.099).

Modification of study

Any modifications to the protocol, such as changes in the study objectives, study design, study method, study intervention, or sample size that affect the interests or safety of the patient, will be agreed upon by NNFTRI (National Nutrition and Food Technology Institute) and approved by the ethics committee of Shahid Beheshti University of Medical Sciences before implementation. NNFTRI will agree upon minor corrections that do not affect the way of the study.

Discussion

Weight regain after bariatric surgery is one of the unpleasant events. The prevalence of weight regain depends on the type of surgery and how long it has been since surgery [5, 6]. Eating behaviors are one of the reasons for weight regain after bariatric surgery [7,8,9,10,11]. Food addiction is one of the eating behaviors that are directly related to the brain-intestine- axis. Recently, growing studies on the role of intestinal microbiota in the etiology and progression of eating disorders are underway [18]. There is a correlation between mood, hormonal changes, stress-induced inflammation, autonomic changes, eating behavior, and intestinal microbiota. It has been suggested that some bacterial species may cause dysregulated eating [20]. Intestinal microbiota affects eating behaviors by affecting the homeostatic and hedonic systems. However, in food addiction, a change in the Brain-Gut-Microbiome (BGM) system shifts this balance to hedonic mechanisms [17]. Hormones such as leptin, serotonin, and oxytocin, have an essential role in the hedonic and homeostatic system and result from eating behaviors and food addiction [21,22,23,24,25]. Bariatric surgery leads to anatomical, neurological, and physiological changes affecting the signaling of the homeostatic and hedonic systems, as well as changes in gastrointestinal hormones and intestinal microbiome, which profoundly affect eating behavior and weighing consequences [39].

It seems based on the available evidence, Probiotic supplementation by modifying the intestinal microbiome can lead to the improvement of food addiction and subsequent weight loss. Therefore, this study aimed to evaluate the effect of probiotic supplementation on the improvement of food addiction and its related hormones and the improvement of anthropometric indices in patients with food addiction and weight regain after bariatric surgery.

Trial status

This trail is in the enrolment stage.

Protocol version

Recruitment began on June 2022 and is expected to be completed on June 2023.

Availability of data and materials

Not applicable.

Abbreviations

mYFAS:

Modified yale food addiction scale

MET:

Metabolic equivalent of task

TFEQ-R18:

Three-Factor Eating Questionnaire

References

  1. Tremmel M, Gerdtham U-G, Nilsson PM, Saha S. Economic burden of obesity: a systematic literature review. Int J Environ Res Public Health. 2017;14(4):435.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Kushner RF. Weight loss strategies for treatment of obesity. Prog Cardiovasc Dis. 2014;56(4):465–72.

    Article  PubMed  Google Scholar 

  3. Arterburn DE, Telem DA, Kushner RF, Courcoulas AP. Benefits and risks of bariatric surgery in adults: a review. JAMA. 2020;324(9):879–87.

    Article  PubMed  Google Scholar 

  4. Welbourn R, Pournaras DJ, Dixon J, Higa K, Kinsman R, Ottosson J, et al. Bariatric surgery worldwide: baseline demographic description and one-year outcomes from the second IFSO global registry report 2013–2015. Obes Surg. 2018;28(2):313–22.

    Article  PubMed  Google Scholar 

  5. Yu Y, Klem ML, Kalarchian MA, Ji M, Burke LE. Predictors of weight regain after sleeve gastrectomy: an integrative review. Surg Obes Relat Dis. 2019;15(6):995–1005.

    Article  PubMed  Google Scholar 

  6. Velapati SR, Shah M, Kuchkuntla AR, Abu-Dayyeh B, Grothe K, Hurt RT, et al. Weight regain after bariatric surgery: prevalence, etiology, and treatment. Curr Nutr Rep. 2018;7(4):329–34.

    Article  PubMed  Google Scholar 

  7. Kaouk L, Hsu AT, Tanuseputro P, Jessri M. Modifiable factors associated with weight regain after bariatric surgery: a scoping review. F1000Res. 2019;8:615. https://doi.org/10.12688/f1000research.18787.2.

  8. Pinto-Bastos A, Conceição EM, Machado PP. Reoperative bariatric surgery a systematic review of the reasons for surgery medical and weight loss outcomes relevant behavioral factors. Obes Surg. 2017;27(10):2707–15.

    Article  PubMed  Google Scholar 

  9. Magro DO, Geloneze B, Delfini R, Pareja BC, Callejas F, Pareja JC. Long-term weight regain after gastric bypass: a 5-year prospective study. Obes Surg. 2008;18(6):648–51.

    Article  PubMed  Google Scholar 

  10. Meany G, Conceição E, Mitchell JE. Binge eating, binge eating disorder and loss of control eating: effects on weight outcomes after bariatric surgery. Eur Eat Disord Rev. 2014;22(2):87–91.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Pizato N, Botelho PB, Gonçalves VS, Dutra ES, De Carvalho K. Effect of grazing behavior on weight regain post-bariatric surgery: a systematic review. Nutrients. 2017;9(12):1322.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Volkow ND, Wise RA, Baler R. The dopamine motive system: implications for drug and food addiction. Nat Rev Neurosci. 2017;18(12):741–52.

    Article  CAS  PubMed  Google Scholar 

  13. Burrows T, Skinner J, McKenna R, Rollo M. Food addiction, binge eating disorder, and obesity: is there a relationship? Behav Sci. 2017;7(3):54.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Ivezaj V, Wiedemann AA, Lawson JL, Grilo CM. Food addiction in sleeve gastrectomy patients with loss-of-control eating. Obes Surg. 2019;29(7):2071–7.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Cassin S, Leung S, Hawa R, Wnuk S, Jackson T, Sockalingam S. Food addiction is associated with binge eating and psychiatric distress among post-operative bariatric surgery patients and may improve in response to cognitive behavioural therapy. Nutrients. 2020;12(10):2905.

    Article  PubMed  PubMed Central  Google Scholar 

  16. DiPatrizio NV. Endocannabinoids and the gut-brain control of food intake and obesity. Nutrients. 2021;13(4):1214.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Gupta A, Osadchiy V, Mayer EA. Brain–gut–microbiome interactions in obesity and food addiction. Nat Rev Gastroenterol Hepatol. 2020;17(11):655–72.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Lam YY, Maguire S, Palacios T, Caterson ID. Are the gut bacteria telling us to eat or not to eat? Reviewing the role of gut microbiota in the etiology, disease progression and treatment of eating disorders. Nutrients. 2017;9(6):602.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Mason BL. Feeding systems and the gut microbiome: gut-brain interactions with relevance to psychiatric conditions. Psychosomatics. 2017;58(6):574–80.

    Article  PubMed  Google Scholar 

  20. Madison A, Kiecolt-Glaser JK. Stress, depression, diet, and the gut microbiota: human–bacteria interactions at the core of psychoneuroimmunology and nutrition. Curr Opin Behav Sci. 2019;28:105–10.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Adam TC, Epel ES. Stress, eating and the reward system. Physiol Behav. 2007;91(4):449–58.

    Article  CAS  PubMed  Google Scholar 

  22. Narayanan NS, Guarnieri DJ, DiLeone RJ. Metabolic hormones, dopamine circuits, and feeding. Front Neuroendocrinol. 2010;31(1):104–12.

    Article  CAS  PubMed  Google Scholar 

  23. Bruijnzeel AW, Corrie LW, Rogers JA, Yamada H. Effects of insulin and leptin in the ventral tegmental area and arcuate hypothalamic nucleus on food intake and brain reward function in female rats. Behav Brain Res. 2011;219(2):254–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Alonso-Alonso M, Woods SC, Pelchat M, Grigson PS, Stice E, Farooqi S, et al. Food reward system: current perspectives and future research needs. Nutr Rev. 2015;73(5):296–307.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Rao RS. Bariatric surgery and the central nervous system. Obes Surg. 2012;22(6):967–78.

    Article  PubMed  Google Scholar 

  26. von der Goltz C, Koopmann A, Dinter C, Richter A, Rockenbach C, Grosshans M, et al. Orexin and leptin are associated with nicotine craving: a link between smoking, appetite and reward. Psychoneuroendocrinology. 2010;35(4):570–7.

    Article  PubMed  Google Scholar 

  27. Yao H, Fan C, Fan X, Lu Y, Wang Y, Wang R, et al. Effects of gut microbiota on leptin expression and body weight are lessened by high-fat diet in mice. Br J Nutr. 2020;124(4):396–406.

    Article  CAS  PubMed  Google Scholar 

  28. Cheng Y-C, Liu J-R. Effect of lactobacillus rhamnosus GG on energy metabolism, leptin resistance, and gut microbiota in mice with diet-induced obesity. Nutrients. 2020;12(9):2557.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Lam V, Su J, Koprowski S, Hsu A, Tweddell JS, Rafiee P, et al. Intestinal microbiota determine severity of myocardial infarction in rats. FASEB J. 2012;26(4):1727–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Queipo-Ortuño MI, Seoane LM, Murri M, Pardo M, Gomez-Zumaquero JM, Cardona F, et al. Gut microbiota composition in male rat models under different nutritional status and physical activity and its association with serum leptin and ghrelin levels. PLoS ONE. 2013;8(5): e65465.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Spetter MS, Hallschmid M. Current findings on the role of oxytocin in the regulation of food intake. Physiol Behav. 2017;176:31–9.

    Article  CAS  PubMed  Google Scholar 

  32. Onaka T, Takayanagi Y. Role of oxytocin in the control of stress and food intake. J Neuroendocrinol. 2019;31(3): e12700.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Erdman S, Poutahidis T. Microbes and oxytocin: benefits for host physiology and behavior. Int Rev Neurobiol. 2016;131:91–126.

    Article  CAS  PubMed  Google Scholar 

  34. Desbonnet L, Clarke G, Traplin A, O’Sullivan O, Crispie F, Moloney RD, et al. Gut microbiota depletion from early adolescence in mice: implications for brain and behaviour. Brain Behav Immun. 2015;48:165–73.

    Article  CAS  PubMed  Google Scholar 

  35. Buffington SA, Di Prisco GV, Auchtung TA, Ajami NJ, Petrosino JF, Costa-Mattioli M. Microbial reconstitution reverses maternal diet-induced social and synaptic deficits in offspring. Cell. 2016;165(7):1762–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. van Galen KA, Ter Horst KW, Serlie MJ. Serotonin, food intake, and obesity. Obes Rev. 2021;22(7):e13210. https://doi.org/10.1111/obr.13210. Epub 2021 Feb 9.

  37. Yano JM, Yu K, Donaldson GP, Shastri GG, Ann P, Ma L, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015;161(2):264–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Fortuna JL. The obesity epidemic and food addiction: clinical similarities to drug dependence. J Psychoactive Drugs. 2012;44(1):56–63.

    Article  PubMed  Google Scholar 

  39. Al-Najim W, Docherty NG, le Roux CW. Food intake and eating behavior after bariatric surgery. Physiol Rev. 2018;98(3):1113–41.

    Article  CAS  PubMed  Google Scholar 

  40. Kazemi A, Noorbala AA, Azam K, Eskandari MH, Djafarian K. Effect of probiotic and prebiotic vs placebo on psychological outcomes in patients with major depressive disorder: a randomized clinical trial. Clin Nutr. 2019;38(2):522–8.

    Article  CAS  PubMed  Google Scholar 

  41. Kazemi A, Noorbala A, Djafarian K. Effect of probiotic and prebiotic versus placebo on appetite in patients with major depressive disorder: post hoc analysis of a randomised clinical trial. J Hum Nutr Diet. 2020;33(1):56–65.

    Article  CAS  PubMed  Google Scholar 

  42. Ahmadi S, Jamilian M, Karamali M, Tajabadi-Ebrahimi M, Jafari P, Taghizadeh M, et al. Probiotic supplementation and the effects on weight loss, glycaemia and lipid profiles in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Hum Fertil. 2017;20(4):254–61.

    Article  CAS  Google Scholar 

  43. Al-Muzafar HM, Amin KA. Probiotic mixture improves fatty liver disease by virtue of its action on lipid profiles, leptin, and inflammatory biomarkers. BMC Complement Altern Med. 2017;17(1):1–9.

    Article  Google Scholar 

  44. Koball AM, Ames G, Goetze RE, Grothe K. Bariatric surgery as a treatment for food addiction? A review of the literature. Curr Addict Rep. 2020;7(1):1–8.

    Article  Google Scholar 

  45. Ivezaj V, Wiedemann AA, Grilo CM. Food addiction and bariatric surgery: a systematic review of the literature. Obes Rev. 2017;18(12):1386–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, SPIRIT, et al. explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;2013:346.

    Google Scholar 

  47. Sanchez M, Darimont C, Panahi S, Drapeau V, Marette A, Taylor VH, et al. Effects of a diet-based weight-reducing program with probiotic supplementation on satiety efficiency, eating behaviour traits, and psychosocial behaviours in obese individuals. Nutrients. 2017;9(3):284.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Haghighinejad H, Tarakemehzadeh M, Jafari P, Jafari M, Ramzi M, Hedayati A. Persian version of the yale food addiction scale 2.0: psychometric analysis and setting cutoff point for the food cravings questionnaire-trait-reduced. Psychiatry Invest. 2021;18(3):179.

    Article  Google Scholar 

  49. Chapman C, Gibson GR, Rowland I. Health benefits of probiotics: are mixtures more effective than single strains? Eur J Nutr. 2011;50(1):1–17.

    Article  CAS  PubMed  Google Scholar 

  50. Timmerman H, Koning C, Mulder L, Rombouts F, Beynen A. Monostrain, multistrain and multispecies probiotics—a comparison of functionality and efficacy. Int J Food Microbiol. 2004;96(3):219–33.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Not applicable.

Access to data

The research team will have access to all data.

Ancillary and post-trial care

Not applicable. No additional care is provided in the trial.

Dissemination policy

The results from the study will be published in a peer reviewed journal. The dataset is available upon request from the corresponding author.

Related articles

Any publication containing the results of this study have not already been published or submitted to any journal.

Who will take informed consent?

F.G and A.Z will introduce the study and will take informed consent from the volunteers.

Patient or Public involvement in the design of the protocol

Patients were not involved in the design of the study protocol.

Name and contact information for the trial sponsor

National Nutrition and Food Technology Research Institute. e-mail address:nutrition@sbmu.ac.ir.

Funding

This research is financially supported by National Nutrition and Food Technology Research Institute. The funding body has no role in the design of the study, the collection, analysis, and interpretation of data, or in the writing of manuscripts.

Author information

Authors and Affiliations

  1. Department of Clinical Nutrition & Dietetics, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    Fateme Ghafouri-Taleghani, Ali Zamanian & Atoosa Saidpour

  2. Obesity Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    Behnaz Abiri

Authors
  1. Fateme Ghafouri-Taleghani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Behnaz Abiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ali Zamanian
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Atoosa Saidpour
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

A.S. and F.G. designed this study. F.G. and A.Z. is conducting the study. F.G. drafted the manuscript of the protocol. A.S. and B.A. critically revised the manuscript. The author(s) read and approved the final manuscript.

Corresponding author

Correspondence to Atoosa Saidpour.

Ethics declarations

Ethics approval and consent to participate

This protocol has been approved by the Medical Ethics Committee of Shahid Beheshti University of Medical Sciences and is in accordance with the Declaration of Helsinki (approved number IR.SBMU.NNFTRI.REC.1400.099). Each subject will sign an informed consent form. Data collected in this study will not be used in any other ancillary studies. This investigation was registered on the Iranian Registry of Clinical Trials on 2022–06-01 (IRCT registration number IRCT20220406054437N1).

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1.

SPIRIT Checklist for Trials.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ghafouri-Taleghani, F., Abiri, B., Zamanian, A. et al. Effects of probiotic supplementation with weight reducing intervention on anthropometric measures, body composition, eating behavior, and related hormone levels in patients with food addiction and weight regain after bariatric surgery: a study protocol for a randomized clinical trial. BMC Nutr 9, 63 (2023). https://doi.org/10.1186/s40795-023-00717-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s40795-023-00717-w

Keywords

BMC Nutrition

ISSN: 2055-0928

Contact us